- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.04. | Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund | ||
| 07.04. | Lilly pays AC Immune $12.5M to expand Alzheimer's collab as asset draws closer to clinic | ||
| 07.04. | Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline | ||
| 07.04. | Sanofi's bispecific scores double respiratory phase 2 wins, but flunks eczema study | ||
| 06.04. | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| 06.04. | Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports | ||
| 03.04. | Months after $100M series A, Syneron closes $150M round to support peptide platform | ||
| 03.04. | Biopharma R&D pipeline shrinks for 1st time in 30 years: report | ||
| 02.04. | 'Portfolio assessment' prompts Ferring to terminate 2 fertility trials | ||
| 02.04. | Immunovant's FcRn inhibitor flunks phase 3 eye disease trials, validating biotech's waning interest | ||
| 02.04. | Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure | ||
| 01.04. | Gilead cancels midstage HIV trial as FDA's clinical hold remains intact | ||
| 01.04. | Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn't tell the whole story | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | ||
| 01.04. | Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down | ||
| 01.04. | 'There isn't as much meat left to cut': Biopharma layoffs maintain slowdown in Q1 | ||
| 31.03. | Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy | ||
| 31.03. | Obesity biotech Ambrosia scores $100M series B to to take next-gen oral GLP-1 into the clinic | ||
| 31.03. | Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play | ||
| 31.03. | Lipella files for bankruptcy, ending dream of developing mouth inflammation drug | ||
| 31.03. | AstraZeneca's Strensiq successor misses phase 3 rare disease goal, denting market expansion plan | ||
| 30.03. | Astellas axes early Sjögren's trial in latest setback for autoimmune disease community | ||
| 30.03. | Blackstone closes record $6.3B life sciences fund | ||
| 30.03. | Kevin Tang uses newfound control of Aurinia to finally take over Kezar | ||
| 30.03. | Viridian's other rival to Amgen's Tepezza scores phase 3 win, but investors need convincing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.